Recent advances in our understanding of the vitamin D endocrine system
- PMID: 173767
Recent advances in our understanding of the vitamin D endocrine system
Abstract
Vitamin D3 gives rise to at least one hormone in which the kidney is utilized as an endocrine system. This hormone arises from 25-OH-D3 which in turn is synthesized in the liver from vitamin D3. The production of this calcium and phosphorus mobilizing hormone, namely 1,25-(OH)2D3, is strongly regulated by the need for calcium and phosphorus. The regulation of its production can occur only after initial 1,25-(OH)2D3 is made and brings about the appearance of 25-OH-D3-24hydroxylase. The need for calcium brings about a stimulation of parathyroid hormone secretion. The parathyroid hormone suppresses the 24-hydroxylase and stimulates the 1-hydroxylase. Alternatively, the need for phosphorus directly stimulates the 1-hydroxylase and suppresses the 24-hydroxylase. The 24-hydroxylation appears to be the initial reaction leading to the inactivation and excretion of vitamin D whereas the 1-hydroxylation is the reaction bringing about the activation of the molecule to 1,25-(OH)2D3. The 1,25-(OH)2D3, the 25-OH-D3 and an analog of 1,25-(OH)2D3, namely 1alpha-OH-D3, are potentially extremely useful in the treatment of metabolic bone diseases such as renal osteodystrophy, hepatically related disorders of calcium and bone metabolism, hypoparathyroidism, and vitamin D dependency disease. The 1alpha-OH-D3 is effective by virtue of its conversion to 1,25-(OH)2D3. The 25-hydroxylation of both 1alpha-OH-D3 and vitamin D3 itself occurs predominantly in the liver. Finally, it is not entirely settled whether 1,25-(OH)2D3 is active directly in all of the functions of viramin D or whether it must be further converted metabolically. A new metabolic pathway for vitamin D has been discovered in which 1,25-(OH)2D3 loses its 26 and 27 carbons to carbon dioxide, producing an unknown metabolite. It is not certain whether this pathway represents degradation of the 1,25-(OH)2D3 or its further activation.
Similar articles
-
Metabolism of vitamin D: current status.Am J Clin Nutr. 1976 Nov;29(11):1258-70. doi: 10.1093/ajcn/29.11.1258. Am J Clin Nutr. 1976. PMID: 187053
-
The kidney as an endocrine organ involved in the function of vitamin D.Am J Med. 1975 Jan;58(1):39-47. doi: 10.1016/0002-9343(75)90531-8. Am J Med. 1975. PMID: 163578 Review.
-
Interrelationships between the key elements of the vitamin D endocrine system: 25-OH-D3-1-hydroxylase, serum calcium and phosphorus levels, intestinal 1,25(OH)2D3, and intestinal calcium binding protein.Adv Exp Med Biol. 1977;81:211-31. doi: 10.1007/978-1-4613-4217-5_23. Adv Exp Med Biol. 1977. PMID: 331899 Review. No abstract available.
-
[Recent advances on vitamin D (author's transl)].Diabete Metab. 1980 Jun;6(2):159-68. Diabete Metab. 1980. PMID: 6997104 Review. French.
-
1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.Dan Med Bull. 2008 Nov;55(4):186-210. Dan Med Bull. 2008. PMID: 19232159 Review.
Cited by
-
Decrease in bone levels of 1,25-dihydroxyvitamin D in women with subcapital fracture of the femur.Calcif Tissue Int. 1993 Feb;52(2):146-8. doi: 10.1007/BF00308324. Calcif Tissue Int. 1993. PMID: 8443691
-
Effects of prednisone and deflazacort on mineral metabolism and parathyroid hormone activity in humans.Calcif Tissue Int. 1984 May;36(3):245-52. doi: 10.1007/BF02405325. Calcif Tissue Int. 1984. PMID: 6432287
-
Intestinal calcium absorption in exogenous hypercortisonism. Role of 25-hydroxyvitamin D and corticosteroid dose.J Clin Invest. 1977 Jul;60(1):253-9. doi: 10.1172/JCI108762. J Clin Invest. 1977. PMID: 874087 Free PMC article.
-
Influence of chemically synthesized vitamin D3 metabolites on calcium metabolism in rats.Calcif Tissue Res. 1977 May;22 Suppl:446-8. doi: 10.1007/BF02064125. Calcif Tissue Res. 1977. PMID: 912565 No abstract available.
-
Use of calciferol and its metabolites and analogues in osteoporosis. Current status.Drugs. 1988 Nov;36(5):513-20. doi: 10.2165/00003495-198836050-00001. Drugs. 1988. PMID: 3063498 Review. No abstract available.